Key statistics
As of last trade Ionis Pharmaceuticals Inc (ISI:MUN) traded at 71.74, -0.66% below its 52-week high of 72.22, set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 71.74 |
|---|---|
| High | 71.74 |
| Low | 71.74 |
| Bid | 70.64 |
| Offer | 70.82 |
| Previous close | 72.22 |
| Average volume | 154.89 |
|---|---|
| Shares outstanding | 161.97m |
| Free float | 160.96m |
| P/E (TTM) | -- |
| Market cap | 13.73bn USD |
| EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:01 GMT.
More ▼
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
- Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
- Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
- Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
- DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
- Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
- Ionis to present at upcoming investor conferences
More ▼
